ABSTRACT
INTRODUCTION:
Mineral metabolism has been recognized as a major risk factor for vascular calcification through trans-differentiation of smooth muscle cells to an osteogenic phenotype. 1 Specifically, higher serum concentrations of phosphate have been shown to be associated with aortic valve calcium (AVC) and mitral annular calcium (MAC) in the setting of kidney disease 2, 3 and in a general population of older adults without known kidney disease or hyperparathyroidism. 4, 5 In addition to its central role in mineral metabolism, activated vitamin D modulates inflammation, which is a key component of coronary artery and valvular calcification as well as atherosclerosis. 6 An independent association of serum 25-hydroxyvitamin D [25(OH)D] with coronary artery calcium (CAC) has been reported, 7 but whether there is a relation of 25(OH)D to valvular calcium is unknown. This study examines whether serum concentrations of 25(OH)D are associated with the prevalence and incidence of AVC and MAC using data from a large multi-ethnic community-based cohort. We hypothesized that both deficient and excess 25(OH)D concentrations would be associated with increased valvular calcium.
METHODS:
Detailed description of the Multi-Ethnic Study of Atherosclerosis (MESA) has been published elsewhere. By study design, all participants underwent a cardiac computed tomography (CT) scan at baseline; a random half had a follow-up cardiac CT at Exam 2 and the other half at Exam 3 (thus varying the time between the baseline and follow-up CTs).
Of the 6,814 participants enrolled in MESA, after accounting for the exclusions noted in Figure 1 , a total of 5,530 participants were included in our analytic sample.
Institutional Review Boards of all participating sites approved the study, and all participants signed informed consent for the MESA Study. The interassay coefficient of variation was 4.4% at 10.4 ng/mL with a lower limit of detection of 2.0 ng/mL for 25(OH)D3 and a coefficient of variation of 4.4% at 9.4 ng/mL with a lower limit of detection of 0.5 ng/mL for 25(OH)D2. Prevalent AVC or MAC was defined as Agatston score >0 at baseline and incident AVC or MAC was defined as detectable AVC or MAC at a follow-up examination in a participant free of AVC or MAC at baseline.
We stratified baseline characteristics by serum 25(OH)D categories defined using the Institute of Medicine guidelines, deficient 25(OH)D as levels <20 ng/ml and adequate as levels ≥20 ng/ml. 16 Frequencies and proportions were reported for categorical variables, and means with standard deviations or medians with interquartile ranges for continuous variables. Variables that were highly skewed (CRP and physical activity) were natural log transformed to approximate a normal distribution. After confirming a linear assumption was not violated, relative risk regression models with robust variance estimation were used to estimate the adjusted prevalence risk ratio Multiplicative interaction terms were created to evaluate for effect modification by variables that may affect vitamin D metabolism. These included: race/ethnicity, age, sex, and eGFR.
All statistical analyses were performed using STATA 13 (StataCorp LP, College Station, TX) and significance was considered at P value of 0.05 or less.
RESULTS:
Of the 5,530 participants included in our analysis, the mean age was 62 ±10 years and 47% were men. Deficient serum 25(OH)D (<20ng/ml) was associated with younger age, black race, presence of diabetes, current smoking status, higher BMI, higher CRP level and lower HDL cholesterol (Table 1) . At baseline, 12.3% of participants had prevalent AVC, leaving 87.7% at risk for incident AVC (Figure 1) . Also, 9.0% had prevalent MAC, leaving 91.0% at risk for incident MAC (Figure 1 ).
Compared to persons with 25(OH)D<20ng/ml, persons with 25(OH)D≥20ng/ml were more likely to have prevalent MAC at baseline (Table 1) . However, there was no statistically significant association between 25(OH)D levels and prevalent MAC nor AVC in multivariable-adjusted analysis (Table 2) .
Over a mean follow-up of 2.5 years, 4.1% of participants free of AVC at baseline developed incident AVC and 4.6% free of MAC developed incident MAC (Figure 1) .
After adjusting for demographic variables, each 10 ng/ml higher serum 25(OH)D was associated with a 15% lower risk of incident MAC but not AVC (Table 3 The findings from this study are partly consistent with the large body of observational evidence that serum 25(OH)D deficiency is a risk marker for future 9 CVD. 7, 26, 27 However whether vitamin D supplementation, a widely available and low cost remedy, can reduce CVD risk remains uncertain at this time. 27 The recent Vitamin D Assessment Study failed to show that high-dose vitamin D supplementation prevented CVD events. institutions can be found at http://www.mesa-nhlbi.org.
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